Common ingredient in energy drinks linked to blood cancer growth, study finds
A common ingredient in some foods and drinks has been linked to an increased risk of blood cancers.
Taurine — a non-essential amino acid that also occurs naturally in the bone marrow, brain, heart and muscles — was found to promote the growth of leukemia cells, according to a study by Wilmot Cancer Institute investigators at the University of Rochester in New York.
The compound is also found in meats, fish and eggs, as well as some energy drinks and protein powders.
Blood Cancer Awareness: Common Types, Signs And Treatment Options
"The key takeaway from this study is that taurine can be used by leukemia cells to promote cancer progression," Jeevisha Bajaj, PhD, an assistant professor in the Department of Biomedical Genetics and a member of Wilmot's Cancer Microenvironment research program, told Fox News Digital.
"Developing new methods to block the cancer cells' ability to take in taurine may improve outcomes for leukemia patients."
Read On The Fox News App
The scientists made the discovery by happenstance as they were investigating the bone marrow with an eye toward improving treatments for blood cancer, according to a press release from the university.
"Our finding that taurine can be produced by the bone marrow microenvironment was completely unexpected and therefore surprising," Bajaj said. "No one had shown this before, and it added critical information to studies of the bone marrow microenvironment, where blood cancers arise and expand."
Kids Who Consume Energy Drinks Are More Prone To Mental Health Disorders, Study Finds
The taurine triggers cancer growth in leukemia cells by promoting a process called glycolysis, which breaks down glucose to produce energy.
In particular, taurine fuels certain types of cancer that emerge from blood stem cells in the bone marrow, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS), the release stated.
The findings were published in the journal Nature.
"We are very excited about these studies because they demonstrate that targeting uptake by myeloid leukemia cells may be a possible new avenue for treatment of these aggressive diseases," said Bajaj.
Terminal Colon Cancer Patient Saved By Breakthrough Treatment
"Our work suggests that developing and testing effective drugs that can impede leukemia cells from using taurine could lead to new treatment approaches for these deadly cancers."
The study did have some limitations, according to the researchers.
"While we can find that taurine levels are high in the bone marrow of mice with leukemia compared to healthy mice, we do not have any evidence on taurine levels in humans with acute myeloid leukemia," Bajah noted. "This is something we hope to study in the future."
Looking ahead, the researchers also plan to study how myelodysplastic syndromes lead to acute leukemia.
Based on the findings, the scientists recommend that patients with leukemia speak with their healthcare providers before adding any new supplements or foods rich in taurine to their diet.
"Since taurine is a common ingredient in energy drinks and is often provided as a supplement to mitigate the side effects of chemotherapy, our work suggests that it may be of interest to carefully consider the benefits of supplemental taurine in leukemia patients," the researchers concluded in the paper.
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, was not involved in the study but commented on the findings.
"The study from the University of Rochester determined that leukemia cells in the bone marrow rely on the amino acid taurine that they don't make themselves," he told Fox News Digital. "Future therapies promise to block the uptake of taurine into leukemia cells."
Further research is needed to determine the exact process for blocking taurine, according to Siegel.
Click Here To Sign Up For Our Health Newsletter
"This is preliminary, but marks an important link between diet and cancer."
The study was primarily funded by the National Cancer Institute, National Institute on Aging, and the National Institute of Diabetes and Digestive and Kidney Disease, all of which are part of the National Institutes of Health. The American Society of Hematology, the Leukemia Research Foundation and Leukemia & Lymphoma Society also provided support.
Some popular energy drinks list taurine as an ingredient.
"There is concern that high-powered energy drinks containing too much taurine could fuel leukemia cells," Siegel told Fox News Digital.
"But at the same time, there is no evidence that these drinks cause the conversion of regular bone marrow cells into leukemia cells."
As the body naturally produces taurine, additional supplementation — especially from energy drinks — is "often unnecessary," according to Dr. Hooman Melamed, a board-certified orthopedic spine surgeon and sports medicine expert based in Marina Del Rey, California.
"From a clinical perspective, I always advise patients to give their bodies what they need, but not to overload them with substances they don't," Melamed, who was not involved in the study, told Fox News Digital.
In general, Melamed said he recommends avoiding energy drinks altogether, especially those containing many synthetic additives or excessive ingredients.
For more Health articles, visit www.foxnews.com/health
"You'll often find 20+ components in these products — many of which you can't pronounce. That alone is a red flag," he cautioned.
"If you don't recognize what's in your food or drink, it's probably not something your body needs."Original article source: Common ingredient in energy drinks linked to blood cancer growth, study finds
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Enrolment concludes in Halia's Phase IIa trial of HT-6184 for MDS
Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk myelodysplastic syndrome (MDS). The two-stage trial is designed to test the therapy in individuals who are intolerant of, refractory to, or ineligible for erythropoiesis-stimulating agents (ESA). It will assess the safety, biomarker response, and efficacy of this allosteric modulator of NEK7, targeting a key inflammatory pathway associated with bone marrow dysfunction in MDS. The trial has enrolled 18 subjects in stage I and an additional 15 in stage II. It includes a 16-week treatment duration, with a continuation phase based on patient response followed. Those who respond might continue therapy, while those who did not, with > 30% reduction in variant allele frequency clone size, could receive further treatment either as a single agent or in conjunction with previous ESA therapy for 16 extra weeks. The main objectives of the study are to assess efficacy via haematological improvement, VAF reduction, clonal suppression, safety, biomarker changes, quality of life, and patient tolerance. Halia noted that an interim analysis after stage I has been conducted, and topline outcomes are anticipated later in the year. Halia Therapeutics CEO Dr David Bearss said: 'Completing enrolment in our Phase IIa MDS study is a major milestone as we continue to validate our mechanism of action targeting innate immune dysregulation. 'This study provides important proof-of-concept data to support the therapeutic potential of HT-6184 in reducing clonal inflammation and improving haematologic outcomes for patients with symptomatic anaemia.' Halia focuses on developing therapies that help restore immune balance in neurodegenerative and inflammatory conditions. Its pipeline also includes HT-6184 plus semaglutide for a planned Phase IIa trial in obesity and Type 2 diabetes, anticipated to start in the third quarter of this year, and HT-4253 for neuroinflammation, currently in a Phase I trial. The company began the Phase II trial last year to investigate HT-6184 in managing post-procedural inflammatory and pain responses. "Enrolment concludes in Halia's Phase IIa trial of HT-6184 for MDS" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Medscape
a day ago
- Medscape
Luspatercept May Prolong Life in Low-Risk MDS
A new analysis from the COMMANDS trial of erythroid maturation agent luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) shows not only sustained, longer-term benefits over epoetin alfa in providing significantly greater independence from transfusions but also, importantly, a promising trend in reducing disease progression and even improving survival. 'We're starting to see a very significant trend in terms of lower rate of transformation and an improvement in survival for patients treated with luspatercept vs epoetin alfa, and I believe this is the first example of this phenomenon ever reported in low risk MDS,' said first author Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, in Houston, in presenting the findings at American Society of Clinical Oncology (ASCO) 2025 in Chicago. In previously reported primary results, the phase 3, global COMMANDS trial showed luspatercept to be the first therapy to have superiority over erythropoiesis-stimulating agents (ESAs) in transfusion-dependent lower-risk MDS. The findings were especially important, as ESAs had for decades represented the first-line treatment for patients with lower-risk MDS. They were described as leading the way to a 'paradigm shift,' with luspatercept subsequently approved in the first-line and second-line treatment of patients with anemia and low-risk MDS. For the new analysis, Garcia-Manero and colleagues reported the first results regarding longer-term duration of responses, safety, and survival of patients treated for more than 2.5 years. In the study, patients in the luspatercept group (n = 182) received 1.0-1.75 mg/kg subcutaneously every 3 weeks, while those in the epoetin alfa arm (n = 181) received 50-1050 IU/kg, with a maximum dose of 80,000 IU, subcutaneously every week, for at least 24 weeks in both groups. In the new analysis, with a median follow-up of 30.6 months in the luspatercept arm and 28.8 months in the epoetin alfa arm, patients treated with luspatercept vs epoetin alfa had a slower rate of disease progression, with just 2.2% vs 5.6% progressing to higher-risk MDS (hazard ratio [HR], 0.388). While the difference was not significant ( P = .1003), 'what we see is a phenomenon that is emerging that is quite significant in that there is indeed a slower rate of progression in the luspatercept arm vs the epoetin alfa,' Garcia-Manero explained. Of note, however, there was no significant difference between the groups in terms of progression to acute myeloid leukemia (4.9% vs 4.4%). Long-Term Treatment Response In terms of long-term treatment response outcomes, red blood cell transfusion independence of at least 12 weeks was achieved by 76.4% (139/182) of patients on luspatercept vs 55.8% (101/181) of those on epoetin alfa (odds ratio [OR], 2.8; P < .0001). The median cumulative duration of transfusion independence through the end of treatment was 150.0 weeks for luspatercept and 95.1 weeks for epoetin alfa (HR, 0.52; P = .0011). 'The results basically show that patients receiving luspatercept are responding for almost a year longer vs the epoetin alfa,' Garcia-Manero noted. Overall Survival Median overall survival in the intention-to-treat population for luspatercept was not reached, while the rate was 46.7 months for epoetin alfa (HR, 0.86). A regression analysis showed six deaths among 68 patients (8.8%) in the luspatercept arm vs 15 deaths among 55 patients (27.3%) in the epoetin alfa arm (HR, 0.330; P = .02). Importantly, the survival curves begin to separate at 36 months — while the 3-year overall survival rates were 63.8% with luspatercept and 62.2% with epoetin alfa, by 5 years, the overall survival rates were 54.0% and 41.8%, respectively, in favor of luspatercept. 'This is very encouraging data suggesting that those patients treated on the luspatercept arm appear to have a longer longevity that those patients in the epoetin alfa arm,' Garcia-Manero said. Furthermore, subgroup analysis of overall survival based on patient characteristics, including transfusion burden, ring sideroblast activity, and baseline serum erythropoietin (EPO) levels, showed survival favoring luspatercept in all groups. 'I think the data this [subanalysis] data is quite important because there have been some questions in terms of what should be the first-line agent to use in a patient with lower risk disease with a [higher] EPO level,' Garcia-Manero said. 'So if we're looking now looking at an intervention that may be changing the natural history of the disease, I think this is quite significant,' he said. Mechanisms? In terms of the mechanisms that might underlie improvements in survival, Garcia-Manero noted that 'there is emerging data that, for instance, [luspatercept] may modulate not only TGF [transforming growth factor] beta but some other innate immunity pathways that are very important for the behavior of the stem cell in MDS,' he explained. 'Furthermore, the [improved overall survival] may not be just mediated by the need for fewer transfusions or higher hemoglobin levels, but there may be actually some biology behind how these drugs work that could be changing natural history of patients with low-risk MDS,' Garcia-Manero said. Findings Are 'Surprising' Commenting on the study, Pamela Sung, MD, PhD, an assistant professor in the Departments of Medicine and Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, who co-moderated the ASCO session, underscored that the results were not anticipated. 'These findings are a surprise, as there has not been a previous study in low-risk MDS that has shown a potential survival benefit,' Sung said in an interview. 'The reason for this improvement is still under investigation as there were no differences between the groups for transformation to AML' — which may have logically explained differences in survival. Of note, 'there was a clear split of the survival curves beginning at 3 years, which is encouraging that these results will hold with longer follow-up,' she added. The findings underscore that 'luspatercept has sustained responses in terms of RBC transfusion independence,' Sung said. 'Preliminary evidence suggests potential disease-modifying activity and survival benefit in low-risk MDS.' Speaking from the audience, Steven Vogl, MD, an oncologist based in the Bronx, New York, speculated on the potential role of subsequent therapies used after failing on epoetin alfa as increasing deaths in that group. 'If patients fail erythropoietin, they may get more transfusions, and/or more treatment or therapies that can cause, for instance, iron overload,' he noted. 'And [that therapy], which was delayed in the luspatercept group, could have had toxicity and made patients weaker, potentially leading to [higher rates of] death in the epoetin alfa group.' He added that while the cause of death can sometimes be hard to pin down in such studies, 'toxicity isn't so hard.' Garcia-Manero responded, 'I totally agree. The mission for us is to start understanding this a little bit better,' he said. 'I don't think it is as simple as [the luspatercept group] just having fewer transfusions, but I may be wrong. The analysis is ongoing.' The study was sponsored by Celgene and Acceleron Pharma.